The study of gemcitabine, GM-CSF and low-dose IL-2 combination for treatment of colon cancer patients showed that this regimen had strong immunologic and antitumor activity associated with immunologic events that strongly resembled those induced by cancer vaccine therapy [20]. Here, IL2 is linked to malignant colon neoplasm.